Investors

Investors

Corporate Profile

We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.

Stock Quote
Exchange
Price
Change (%)
Volume
Data as of
Exchange
Price
Change (%)
Volume
Data as of
More >>

Recent News

Date Title and Summary Additional Formats
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – January 31, 2019
LYON, France , Feb. 06, 2019 (GLOBE NEWSWIRE) --   Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon - France Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the
View HTML
Toggle Summary ERYTECH Presents TRYbeCA-1 Trial-in-Progress Poster at the 2019 ASCO GI Annual Meeting
LYON, France and CAMBRIDGE, Mass. , Jan. 18, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, announced that a poster entitled
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – December 31, 2018
LYON, France , Jan. 08, 2019 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon - France Listing markets: Euronext Paris from Euronext (Market segment B -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2018
Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon - France LYON, France , Dec. 05, 2018 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment B -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States
View HTML
More >>

Upcoming Events

There are currently no events to display.

RECEIVE E-MAIL ALERTS

Copyright West LLC. Minimum 15 minutes delayed.

Top